Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412972 | 0.89 | P2RX7 (0.65) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL5181399 | 0.85 | P2RX7 (0.64) | P2RX7ABCB11ALDH1A1MEN1NR1I2 | |
| SCHEMBL1412845 | 0.84 | P2RX7 (0.59) | P2RX7ABCB11L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL5623437 | 0.82 | P2RX7 (0.59) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL7253390 | 0.82 | P2RX7 (0.79) | P2RX7ABCB11ALDH1A1MEN1NR1I2 | |
| SCHEMBL1412836 | 0.79 | P2RX7 (0.74) | P2RX7ABCB11 | |
| SCHEMBL1412852 | 0.79 | P2RX7 (1.00) | P2RX7ABCB11ALDH1A1KDM4E | |
| SCHEMBL27667221 | 0.79 | P2RX7 (0.47) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL6771226 | 0.78 | P2RX7 (0.52) | P2RX7ABCB11ALDH1A1MEN1NR1I2 | |
| SCHEMBL1412907 | 0.78 | P2RX7 (0.71) | P2RX7ABCB11MEN1NR1I2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041663-A1 | P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2026-02-26 | — | — | WO | disclosed |
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235657-B2 | Methods for preparing P2X7 inhibitors | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235657-B2 | Methods for preparing P2X7 inhibitors | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235657-B2 | Methods for preparing P2X7 inhibitors | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| CN-1980902-A | Method for preparing 5-'4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h'1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers | PFIZER (US) | 2007-06-13 | — | — | CN | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050288256-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1310493-B1 | N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6927219-B2 | N-alkyl-adamantyl triazinyl benzamide derivatives | PFIZER INC. (US) | 2005-08-09 | — | — | US | disclosed |
| CN-1585755-A | Benzamide and heteroarylamide as P2X7 receptor antagonists | PFIZER PROD INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1448535-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030144293-A1 | N-alkyl-adamantyl triazinyl benzamide derivatives | PFIZER INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003042191-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003042190-A1 | N-ALKYL-ADAMANTYL DERIVATIVES AS P2X7-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-1310493-A1 | N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists | Pfizer Products Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 866/4885L3MBTL1 4609/4885 |
| US-20050288256-A1 | Methods for preparing P2X7 inhibitors | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885ABCB11 89/4885L3MBTL1 4381/4885 |
| US-20030144293-A1 | N-alkyl-adamantyl triazinyl benzamide derivatives | AIFM1, BAD, BID | P2RX7 1205/4885ABCB11 3582/4885L3MBTL1 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.